Loading...

© 2026 MedXY

Contact us About us Privacy Policy MedXY story

MedXY News - cirrhosis

MedXY AI/MedXY News/Tag: cirrhosis

MedXY News

EnglishTag

cirrhosis

20 · 20 / page

Ask MedXY AI

type 2 diabetes clinical trial heart failure immunotherapy obesity atrial fibrillation cardiovascular risk Cardiology biomarkers clinical trials Hypertension oncology critical care public health artificial intelligence Alzheimer's disease breast cancer diabetes cardiovascular disease type 1 diabetes nutrition chronic kidney disease

Latest news

Tag

New A-TANGO Organ Failure Score Refines ACLF Diagnosis and Risk Stratification in Global Cohorts

Critical Carecirrhosisprognosis

New A-TANGO Organ Failure Score Refines ACLF Diagnosis and Risk Stratification in Global Cohorts

By MedXY|Jul 26, 2026

A new organ failure score, A-TANGO, improves ACLF diagnosis and risk stratification compared to standard CLIF-C criteria, validated in large international cohorts.

Circulating Methylated SEPT9 as a Novel Biomarker for Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients

Clinical Updatesalpha-fetoproteincancer biomarkers

Circulating Methylated SEPT9 as a Novel Biomarker for Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients

By MedXY|Jul 9, 2026

Combining circulating methylated SEPT9 with alpha-fetoprotein significantly enhances early hepatocellular carcinoma detection in cirrhotic patients, outperforming AFP alone and allowing improved surveillance sensitivity and specificity.

HBsAg Seroclearance Lowers Hepatocellular Carcinoma Risk Beyond Viral Suppression in Cirrhosis, but Does Not Reduce Hepatic Decompensation

Gastroenterologychronic hepatitis Bcirrhosis

HBsAg Seroclearance Lowers Hepatocellular Carcinoma Risk Beyond Viral Suppression in Cirrhosis, but Does Not Reduce Hepatic Decompensation

By MedXY|Jun 10, 2026

In NA-treated cirrhotic chronic hepatitis B with complete viral suppression, HBsAg seroclearance was linked to lower HCC risk but not lower hepatic decompensation, reinforcing functional cure as a meaningful but incomplete clinical endpoint

Primary vs Specialist Palliative Care in End-Stage Liver Disease: Interpreting the 2026 Cluster Randomized Trial in the Broader Evidence Base

Clinical Updatescirrhosisend-stage liver disease

Primary vs Specialist Palliative Care in End-Stage Liver Disease: Interpreting the 2026 Cluster Randomized Trial in the Broader Evidence Base

By MedXY|Jun 9, 2026

A major 2026 cluster randomized trial shows that palliative care delivered by trained hepatologists is noninferior to specialist palliative care for improving quality of life in end-stage liver disease, supporting scalable integrated models

Chronic Kidney Disease Worsens Short-Term Outcomes in Hospitalized Patients With Cirrhosis Across a Global Cohort

Gastroenterologyacute kidney injurychronic kidney disease

Chronic Kidney Disease Worsens Short-Term Outcomes in Hospitalized Patients With Cirrhosis Across a Global Cohort

By MedXY|Jun 7, 2026

In a large international prospective cohort of hospitalized patients with cirrhosis, chronic kidney disease was common, clustered with metabolic risk, and strongly associated with acute kidney injury, more decompensation, and higher in-hosp

Targeted Galectin-3 Inhibition for Portal Hypertension: Insights from the NAVIGATE Trial and Belapectin’s Role in MASH Cirrhosis

Clinical UpdatesBelapectincirrhosis

Targeted Galectin-3 Inhibition for Portal Hypertension: Insights from the NAVIGATE Trial and Belapectin’s Role in MASH Cirrhosis

By MedXY|Jun 1, 2026

This review synthesizes clinical evidence for Belapectin, a Galectin-3 inhibitor, focusing on its ability to prevent esophageal varices in patients with MASH cirrhosis and portal hypertension as demonstrated in the NAVIGATE trial.

Non-contrast abbreviated MRI shows superior accuracy to ultrasound for hepatocellular carcinoma surveillance in cirrhosis: interim prospective trial results

Gastroenterologyabbreviated MRIcirrhosis

Non-contrast abbreviated MRI shows superior accuracy to ultrasound for hepatocellular carcinoma surveillance in cirrhosis: interim prospective trial results

By MedXY|May 13, 2026

A prospective trial found that non-contrast abbreviated MRI detected hepatocellular carcinoma in cirrhotic patients far better than ultrasound, with most MRI-detected tumors found at an early, potentially curable stage.

A New Framework to Refine Hepatocellular Cancer Surveillance with Risk Stratification Models

Gastroenterologycirrhosishepatocellular carcinoma

A New Framework to Refine Hepatocellular Cancer Surveillance with Risk Stratification Models

By MedXY|Apr 23, 2026

The Translational Liver Cancer Consortium proposes a structured framework for developing and validating risk models to optimize HCC surveillance, addressing gaps in current clinical guidelines.

Stratifying Risk in Incidentally Detected Splenomegaly: Quantitative Thresholds for Hematologic and Hepatic Surveillance

Clinical Updatescirrhosisliver cancer

Stratifying Risk in Incidentally Detected Splenomegaly: Quantitative Thresholds for Hematologic and Hepatic Surveillance

By MedXY|Mar 22, 2026

This review synthesizes large-scale cohort data defining specific spleen length and volume thresholds that significantly increase the 5-year absolute risk of hematologic cancers and chronic liver disease.

Routine 5–7 Day Antibiotic Prophylaxis After Upper GI Bleeding in Cirrhosis: New Meta-analysis Questions the Mortality Benefit

Gastroenterologyantibiotic prophylaxisbayesian meta-analysis

Routine 5–7 Day Antibiotic Prophylaxis After Upper GI Bleeding in Cirrhosis: New Meta-analysis Questions the Mortality Benefit

By MedXY|Nov 25, 2025

A 2025 bayesian meta-analysis of 14 RCTs (n=1,322) found shorter or no antibiotic prophylaxis after upper GI bleeding in cirrhosis was highly likely to be noninferior for mortality, though it increased reported bacterial infections. Study l

Cirrhosis Incidence Across Socioeconomic and Demographic Groups in Sweden: A Register-Based Cohort Study and Its Global Context

Clinical UpdatesALDcirrhosis

Cirrhosis Incidence Across Socioeconomic and Demographic Groups in Sweden: A Register-Based Cohort Study and Its Global Context

By MedXY|Nov 24, 2025

This review synthesizes evidence on rising cirrhosis incidence in Sweden, highlighting marked socioeconomic disparities particularly in ALD- and MASLD-related cirrhosis, with broader implications across high-income countries for targeted pr

Rivaroxaban in Cirrhosis: A Promising Strategy to Prevent Portal Hypertension Complications

Gastroenterologyanticoagulationcirrhosis

Rivaroxaban in Cirrhosis: A Promising Strategy to Prevent Portal Hypertension Complications

By MedXY|Oct 28, 2025

The CIRROXABAN trial evaluates rivaroxaban’s efficacy and safety in preventing complications of portal hypertension in cirrhotic patients, suggesting improved complication-free survival without significantly increasing major bleeding

Rivaroxaban in Cirrhosis: A Promising Strategy to Prevent Portal Hypertension Complications

Gastroenterologyanticoagulationcirrhosis

Rivaroxaban in Cirrhosis: A Promising Strategy to Prevent Portal Hypertension Complications

By MedXY|Oct 28, 2025

The CIRROXABAN trial evaluates rivaroxaban’s efficacy and safety in preventing complications of portal hypertension in cirrhotic patients, suggesting improved complication-free survival without significantly increasing major bleeding

Unraveling Non-Acute Decompensation in Cirrhosis: A Distinct Clinical and Pathophysiological Entity with Prognostic Implications

Gastroenterologycell death markerscirrhosis

Unraveling Non-Acute Decompensation in Cirrhosis: A Distinct Clinical and Pathophysiological Entity with Prognostic Implications

By MedXY|Oct 28, 2025

Non-acute decompensation of cirrhosis (NAD) represents a distinct clinical state characterized by elevated cell death markers and moderate prognosis. Identifying predictors such as ascites severity and biomarkers Gasdermin-D and RIPK3 may g

RIPK3 as a Prognostic Biomarker in Acute Decompensation of Cirrhosis: Advancing Risk Stratification and Therapeutic Targeting

Critical CareACLFacute decompensation

RIPK3 as a Prognostic Biomarker in Acute Decompensation of Cirrhosis: Advancing Risk Stratification and Therapeutic Targeting

By MedXY|Oct 28, 2025

RIPK3-associated necroptosis critically drives organ failure and mortality in acute decompensation and ACLF, with its plasma levels robustly predicting outcomes and improving prognostic models to guide personalized therapies.

Long-Term Real-World Effectiveness, Safety, and Liver Stiffness Changes with Obeticholic Acid in Primary Biliary Cholangitis

GastroenterologyAxit obeticholiccirrhosis

Long-Term Real-World Effectiveness, Safety, and Liver Stiffness Changes with Obeticholic Acid in Primary Biliary Cholangitis

By MedXY|Oct 28, 2025

This study confirms the sustained effectiveness and safety of obeticholic acid (OCA) in primary biliary cholangitis (PBC) over a 2-year median follow-up, highlighting its impact on liver stiffness and fibrosis progression, especially in bio

Early Portopulmonary Hypertension in Cirrhosis: A Prognostic Marker of Increased Mortality

Cardiologycirrhosismortality prediction

Early Portopulmonary Hypertension in Cirrhosis: A Prognostic Marker of Increased Mortality

By MedXY|Oct 27, 2025

Early-stage portopulmonary hypertension, defined by revised 2022 ESC/ERS criteria, independently predicts mortality in patients with cirrhosis, underscoring the importance of systematic screening and early intervention.

The THEMATIC Trial: Advancing Microbiota Transplantation to Prevent Hepatic Encephalopathy Recurrence in Cirrhosis

Clinical Updatescirrhosisfecal microbiota transplantation

The THEMATIC Trial: Advancing Microbiota Transplantation to Prevent Hepatic Encephalopathy Recurrence in Cirrhosis

By MedXY|Oct 8, 2025

The THEMATIC phase II trial demonstrates that fecal microbiota transplantation (FMT) is safe and reduces HE recurrence in cirrhosis, independent of dose, route, or donor diet, with gut microbiota engraftment linked to clinical outcomes.

Low-Dose Hydrocortisone in Cirrhotic Patients With Septic Shock: A Double-Blind Randomised Placebo-Controlled Trial

Clinical Updatesadrenal insufficiencycirrhosis

Low-Dose Hydrocortisone in Cirrhotic Patients With Septic Shock: A Double-Blind Randomised Placebo-Controlled Trial

By MedXY|Oct 1, 2025

This trial evaluated low-dose hydrocortisone in cirrhotic patients with septic shock, finding no improvement in 28-day mortality or shock resolution compared to placebo.

Pre-emptive TIPS vs Glue Obliteration for Acute Fundal Variceal Bleeding in Cirrhosis: Key Insights from the GAVAPROSEC Trial

Clinical Updatescirrhosisclinical trial

Pre-emptive TIPS vs Glue Obliteration for Acute Fundal Variceal Bleeding in Cirrhosis: Key Insights from the GAVAPROSEC Trial

By MedXY|Oct 1, 2025

The GAVAPROSEC trial demonstrates that pre-emptive TIPS significantly reduces 1-year mortality and rebleeding in cirrhotic patients with acute fundal gastric variceal bleeding compared to glue obliteration plus NSBB.

Ask MedXY AI

Most popular

New A-TANGO Organ Failure Score Refines ACLF Diagnosis and Risk Stratification in Global Cohorts

MIND Diet Linked to Lower Cancer Risk and Reduced Mortality, With New Genetic Insights

High-Intensity Resistance Training Improves Lower Limb Strength More Than Low-Moderate Intensity in Older Adults

Clinical Updates

Retatrutide in Type 2 Diabetes and MASLD: Integrative Evidence on Body Composition and Liver Fat Reduction

Family Medicine & Nutrition

The Curious Scent of Feces: The Dual Identity and Health Secrets of Skatole